Commercial

A timeline of key moments in the development of checkpoint inhibitors
A timeline of key moments in the development of checkpoint inhibitors
Laura Entis
October 17, 2018
5:00 am

Immunotherapy’s modern era has been characterized by a tremendous amount of scientific and regulatory activity. Trace the road to the Nobel.

Pharma companies can address the opioid crisis by changing their approach to marketing
Pharma companies can address the opioid crisis by changing their approach to marketing
Martina Rozumberkova
October 2, 2018
6:00 am

As pressure to address the opioid crisis mounts, pharma companies are evaluating their marketing strategies and tactics.

Half year pro ad report 2018: Journal ad pages jump 1.4%
Half year pro ad report 2018: Journal ad pages jump 1.4%
MMM Staff
October 2, 2018
6:00 am

Spending in medical journals during the first half of 2018 may not have reached the levels seen in the recent past. At the same time, pharma companies don’t appear to be trimming their investments.

FDA turns attention to vapes in latest version of Real Cost anti-tobacco campaign
FDA turns attention to vapes in latest version of Real Cost anti-tobacco campaign
Alison Kanski
September 19, 2018
10:13 am

An estimated 10.7 million teens are vaping or thinking about it.

With a nod from the FDA, Teva enters white-hot migraine market
With a nod from the FDA, Teva enters white-hot migraine market
Laura Entis
September 18, 2018
9:51 am

Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.

7 must-haves for effective market access programs
7 must-haves for effective market access programs
Karen J. Bannan
September 7, 2018
7:00 am

How does one create an effective market access program in the current healthcare environment? Experts share seven tips for success.

After failure of generic fish oil trial, some caution against read-across to Vascepa study
After failure of generic fish oil trial, some caution against read-across to Vascepa study
Alison Kanski
August 28, 2018
5:05 pm

Amarin’s Vascepa trial is set to read out results by the end of September.

Got name? A peek into the sometimes bizarre land of pharma brand-naming
Got name? A peek into the sometimes bizarre land of pharma brand-naming
Laura Entis
August 27, 2018
11:00 am

As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.

Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
Alison Kanski
August 24, 2018
1:51 pm

The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.

Pfizer lawsuit could clear path for biosimilars
Pfizer lawsuit could clear path for biosimilars
Alison Kanski
August 23, 2018
5:00 pm

Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.

  • From Our Partners